170 related articles for article (PubMed ID: 21835316)
1. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes).
Chung SC; Hlatky MA; Faxon D; Ramanathan K; Adler D; Mooradian A; Rihal C; Stone RA; Bromberger JT; Kelsey SF; Brooks MM;
J Am Coll Cardiol; 2011 Aug; 58(8):810-9. PubMed ID: 21835316
[TBL] [Abstract][Full Text] [Related]
2. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
Brooks MM; Chung SC; Helmy T; Hillegass WB; Escobedo J; Melsop KA; Massaro EM; McBane RD; Hyde P; Hlatky MA;
Circulation; 2010 Oct; 122(17):1690-9. PubMed ID: 20937978
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group
Am Heart J; 2008 Sep; 156(3):528-536, 536.e1-5. PubMed ID: 18760137
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
Tamis-Holland JE; Lu J; Korytkowski M; Magee M; Rogers WJ; Lopes N; Mighton L; Jacobs AK;
J Am Coll Cardiol; 2013 Apr; 61(17):1767-76. PubMed ID: 23500245
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
Hlatky MA; Boothroyd DB; Melsop KA; Kennedy L; Rihal C; Rogers WJ; Venkitachalam L; Brooks MM;
Circulation; 2009 Dec; 120(25):2550-8. PubMed ID: 19920002
[TBL] [Abstract][Full Text] [Related]
6. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.
Chaitman BR; Hardison RM; Adler D; Gebhart S; Grogan M; Ocampo S; Sopko G; Ramires JA; Schneider D; Frye RL;
Circulation; 2009 Dec; 120(25):2529-40. PubMed ID: 19920001
[TBL] [Abstract][Full Text] [Related]
7. Risk factor control for coronary artery disease secondary prevention in large randomized trials.
Farkouh ME; Boden WE; Bittner V; Muratov V; Hartigan P; Ogdie M; Bertolet M; Mathewkutty S; Teo K; Maron DJ; Sethi SS; Domanski M; Frye RL; Fuster V
J Am Coll Cardiol; 2013 Apr; 61(15):1607-15. PubMed ID: 23500281
[TBL] [Abstract][Full Text] [Related]
8. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
Khan AA; Chung MJ; Novak E; Brown DL
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
[TBL] [Abstract][Full Text] [Related]
9. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Brooks MM; Chaitman BR; Nesto RW; Hardison RM; Feit F; Gersh BJ; Krone RJ; Sako EY; Rogers WJ; Garber AJ; King SB; Davidson CJ; Ikeno F; Frye RL;
Circulation; 2012 Oct; 126(17):2115-24. PubMed ID: 23008442
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of therapies for type 2 diabetes and coronary artery disease.
; Frye RL; August P; Brooks MM; Hardison RM; Kelsey SF; MacGregor JM; Orchard TJ; Chaitman BR; Genuth SM; Goldberg SH; Hlatky MA; Jones TL; Molitch ME; Nesto RW; Sako EY; Sobel BE
N Engl J Med; 2009 Jun; 360(24):2503-15. PubMed ID: 19502645
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.
Dagenais GR; Lu J; Faxon DP; Bogaty P; Adler D; Fuentes F; Escobedo J; Krishnaswami A; Slater J; Frye RL;
J Am Coll Cardiol; 2013 Feb; 61(7):702-11. PubMed ID: 23410541
[TBL] [Abstract][Full Text] [Related]
13. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Sobel BE; Hardison RM; Genuth S; Brooks MM; McBane RD; Schneider DJ; Pratley RE; Huber K; Wolk R; Krishnaswami A; Frye RL;
Circulation; 2011 Aug; 124(6):695-703. PubMed ID: 21768545
[TBL] [Abstract][Full Text] [Related]
14. BARI 2D: A Reanalysis Focusing on Cardiovascular Events.
Genuth SM; Vlachos H; Brooks MM; Bantle JP; Chaitman BR; Green J; Kelsey SF; King SB; McBane R; Sako EY; Schneider DJ; Steffes M; Frye RL;
Mayo Clin Proc; 2019 Nov; 94(11):2249-2262. PubMed ID: 31590967
[TBL] [Abstract][Full Text] [Related]
15. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.
Kim LJ; King SB; Kent K; Brooks MM; Kip KE; Abbott JD; Jacobs AK; Rihal C; Hueb WA; Alderman E; Sing IR; Attubato MJ; Feit F;
JACC Cardiovasc Interv; 2009 May; 2(5):384-92. PubMed ID: 19463459
[TBL] [Abstract][Full Text] [Related]
16. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.
Dagenais GR; Lu J; Faxon DP; Kent K; Lago RM; Lezama C; Hueb W; Weiss M; Slater J; Frye RL;
Circulation; 2011 Apr; 123(14):1492-500. PubMed ID: 21444887
[TBL] [Abstract][Full Text] [Related]
17. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial.
Damluji AA; Cohen ER; Moscucci M; Myerburg RJ; Cohen MG; Brooks MM; Rich MW; Forman DE
Int J Cardiol; 2017 Aug; 241():35-40. PubMed ID: 28314486
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial.
Wolk R; Bertolet M; Brooks MM; Pratley RE; Sobel BE; Frye RL; Singh P; Calvin AD; Rutter MK; Mooradian AD; Somers VK;
Eur J Prev Cardiol; 2016 Jan; 23(1):50-8. PubMed ID: 25073857
[TBL] [Abstract][Full Text] [Related]
19. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease.
Rutter MK; Nesto RW
Diab Vasc Dis Res; 2010 Jan; 7(1):69-72. PubMed ID: 20368235
[TBL] [Abstract][Full Text] [Related]
20. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).
Schwartz L; Kip KE; Alderman E; Lu J; Bates ER; Srinivas V; Bach RG; Mighton LD; Feit F; King S; Frye RL;
Am J Cardiol; 2009 Mar; 103(5):632-8. PubMed ID: 19231325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
